title: Protein p53--structure, function, and possible therapeutic implications.
abstract: Cell cycle is driven by a number of positive and negative regulatory phosphorylation and dephosphorylation events that ultimately influence the activity of transcription factors. Normal skin architecture depends on the regulation mechanisms of cell proliferation and differentiation and on apoptosis. Complex interaction of different factors in the regulation of these mechanisms, aimed at maintaining constant desquamation, is often changed in skin diseases. The main difference between normal cells and tumor cells results from discrete changes in specific genes important for cell proliferation control mechanisms and tissue homeostasis. These genes are mainly proto-oncogenes or tumor-suppressor genes, and their mutation could play a role in cell hyperproliferation and carcinogenesis. Tumor-suppressor genes normally function as a physiological barrier against clonal expansion or mutation accumulation in the genome. They also control and arrest growth of the cells that hyperproliferate due to oncogene activity. Alteration or DNA damage in tumor-suppressor genes and oncogenes are considered key events in human carcinogenesis. Tumor-suppressor protein p53 is an important transcription factor, which plays a central role in the cell cycle regulation mechanisms and cell proliferation control, and its inactivation is considered a key event in human carcinogenesis. The role of p53 protein in the cell cycle, high proportion of tumors with mutated p53 gene, and accumulation of significant amount of knowledge on molecular biology of this protein make this molecule especially attractive for development of new therapeutic approaches. Main strategies for development of new antineoplastic therapies are based on "wild-type" p53 protein acting as a tumor suppressor, selective apoptosis inductor, and a protein able to arrest cell cycle.
authors.affiliation: Department of Dermatovenerology, Rijeka University Hospital Center, Rijeka, Croatia. tanjabatinac@net.hr
authors.forename: Tanja
authors.initials: T
authors.lastname: Batinac
authors.forename: Franjo
authors.initials: F
authors.lastname: Gruber
authors.forename: Jasna
authors.initials: J
authors.lastname: Lipozencić
authors.forename: Gordana
authors.initials: G
authors.lastname: Zamolo-Koncar
authors.forename: Adalbert
authors.initials: A
authors.lastname: Stasić
authors.forename: Ines
authors.initials: I
authors.lastname: Brajac
mesh_terms: D016158:Genes, p53 / Q000502:physiology; D006801:Humans; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry / Q000502:physiology / Q000627:therapeutic use
chemical_list: D016159:Tumor Suppressor Protein p53